Agilent Technologies

A

Market cap $41.4B

Agilent Technologies, Inc. (A) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Agilent (A) reported earnings 30 days ago. What's next for the stock?

Bloomberg's 2026 Dividend Focus list highlights 14 ‘safer' stocks with free cash flow yields exceeding dividend yields, signaling potential buy opportunities. Top projected net gainers for 2026 include Marvell Technology (MRVL), Nike (NKE), and PT Telekom Indonesia (TLK), with analyst-estimated gains up to 37.98%. Four ‘IDEAL' stocks—Aviva, Sodexo, Danske Bank, and Western Midstream—offer dividends from $1,000 invested greater than their share price, meeting the dogcatcher ‘watch to buy' threshold.

SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #BringGreatScienceToLife--Agilent Technologies Inc. (NYSE: A) today announced that CEO Padraig McDonnell and CFO Adam Elinoff will present at the 44th Annual J.P. Morgan Healthcare Conference at 9 to 9:40 a.m. PST on Tuesday, Jan. 13, 2026. A live audio webcast and replay of the presentation will be available through Agilent's Investor Relations website. About Agilent Technologies Agilent Technologies, Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technolog.

Agilent Technologies, Inc. (A) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

The Magnificent 7 AI tech stocks have served as the rocket fuel propelling the S&P 500 on its bull run over the past few years.

Examine Agilent's (A) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc (NYSE: A) today announced the release of a new 21 CFR Part 11 compliance software for the Agilent xCELLigence Real-Time Cell Analysis (RTCA) eSight system. The software includes a compliance license and enhanced security features, allowing this multiplex live-cell analysis system to be deployed not only in drug discovery and development labs but now also in GMP-regulated manufacturing and quality control settings. Extending the plat.

A group of dividend raisers OBT, UBSI, DDS, PATK and A stand out as investors seek stability amid volatile markets, rate-cut hopes and mixed economic signals.

Agilent Technologies delivered strong Q4 2025 results, with revenue and EPS beating expectations and robust growth in Life Sciences and Diagnostics segment. Management forecasts FY26 revenue growth of 6% and normalized EPS between $5.86 and $6.00, signaling continued solid performance. Agilent now trades at a 6% premium to fair value after a 23% rally, outpacing the S&P 500 handily since my August coverage.